Drug Profile
Research programme: neurological disease therapeutics - Servier/Crossbeta Biosciences
Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Crossbeta Biosciences; Servier
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Neurological-disorders in France
- 28 Nov 2019 No recent reports of development identified for research development in Neurological-disorders in Netherlands
- 05 Oct 2015 Early research in Neurological disorders in France (unspecified route)